Survodutide trial had a big dropout rate - does that put anyone else off?

[cashew_ramblerog]

There's a video worth checking out on this. Survo apparently has a rough dropout rate and doesn't look like it'll join the top tier of this drug class.
Zealand Pharma's stock dropped roughly 25 percent after that trial data came out.
Investors tend to weigh tolerability heavily when judging whether something will actually succeed commercially, and a dropout rate that's two to four times steeper than wegovy's doesn't paint survo in a great light.
Still, digging through some of the early numbers, there's no rush to abandon survodutide just yet, a couple kits are already sitting around, hoping the way it targets liver and visceral fat specifically ends up being a genuine fit for this particular body type.

 

[dozydabbler]

Picked some shares up a few months back and rode out the dip without selling. Sitting around 10 percent up now. My guess is the big institutions have already baked the retatrutide approval into the price, but I doubt regular retail investors have caught up yet. Also not convinced the institutional side fully grasps just how big a shift GLP-1 medications actually represent. Feels like only the people actually running syringes day to day really understand it. Whichever pharma companies manage to ride this trend look set up well going forward.

 

[evidence-based]

Just my 2 cents: skin reactions ruled out reta for me, so survo became my pick. It gave me zero side effects and solid results for roughly a year alongside tirz. No complaints from me, though cost-wise it can't compete with reta.

 

[PulseBTW445]

Cagri was my attempt at hitting another receptor. Could be coincidence, but around day one or two of last year's vacation a tiny third dose flattened me for a full day, and I dropped it. Survo came next, treated me well and carried me to goal. New goal now, so survo titration is coming. Schedule: tirz 10 on a six-day cycle, survo 1.5 on a six-day cycle too, three days apart.

 

[tipsyramen]

My main takeaway was that some people, a minority, respond to sema better than to tirz. Since we lean on overall averages (which favor tirz at population level), that minority may get treated poorly. With glucagon agonism entering the picture, it's fair to expect that same group could respond best to survo. Who they are is unknowable without testing, and nobody tests, but they seem to exist.